Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verve Therapeutics, Inc. - Common Stock (NQ: VERV )

8.580 +0.870 (+11.28%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verve Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Verve Therapeutics Stock Skids On The FDA's Long List Of Gene-Editing Concerns
The company has a long list of issues to address to satisfy the FDA's worries. 
Via Investor's Business Daily
Looking Into Verve Therapeutics's Recent Short Interest
Verve Therapeutics's (NASDAQ:VERV) short percent of float has fallen 10.98% since its last report. The company recently reported that it has 10.05 million shares sold short, which is 29.91% of all... 
Via Benzinga
Verve Therapeutics to Participate in Upcoming Investor Conferences
From Verve Therapeutics
Via GlobeNewswire
Dow Surges 400 Points; Crude Oil Down 1%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 400 points on Monday. 
Via Benzinga
Why Verve Therapeutics' Stock Dropped 26.33% on Monday
A trial for the company's lead therapy was put on hold. 
Via The Motley Fool
Why Shares Of CRISPR-Focused Verve Therapeutics Just Took A Grim Turn
The company is testing a CRISPR-based approach to high cholesterol. 
Via Investor's Business Daily
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session
Gainers Dragon Victory International Limited (NASDAQ: LYL) surged 52.2% to $0.6870. 
Via Benzinga
Looking Into Verve Therapeutics's Recent Short Interest
Verve Therapeutics's (NASDAQ:VERV) short percent of float has fallen 11.53% since its last report. The company recently reported that it has 10.73 million shares sold short, which is 33.6% of all... 
Via Benzinga
Dow Jumps Over 200 Points; Verve Therapeutics Shares Plummet
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 200 points on Monday. 
Via Benzinga
Dow Up Triple Digits Ahead Of Busy Week
The Dow Jones Industrial Average is up 212 points midday, continuing Friday's flourish, while the Nasdaq Composite and S&P 500 Index sit more hesitantly in the black. 
Via Talk Markets
IAA Stock Moves as Ritchie Bros Acquires Company in $7.3 Billion Deal
IAA (IAA) stock is moving on Monday thanks to a massive acquisition $7.3 billion deal with Ritchie Bros Auctioneers (RBA). 
Via InvestorPlace
Verve Therapeutics Shares Tumble After FDA Hold On Trial For Elevated Cholesterol Level Candidate
Via Benzinga
Why Is Verve Therapeutics (VERV) Stock Down 28% Today?
Verve Therapeutics (VERV) stock is taking a beating on Monday following bad news from the U.S. Food and Drug Administration (FDA). 
Via InvestorPlace
TreeHouse Foods, Ritchie Bros. Auctioneers, Beam Therapeutics And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded mostly higher, with the Dow Jones gaining more than 150 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
US Stocks Mixed; Dow Rises Over 50 Points
U.S. stocks traded mixed this morning, with the Dow Jones gaining over 50 points on Monday. 
Via Benzinga
Verve Crashes After FDA Halts Plan To Test Gene Editor In People
Verve Therapeutics hopes to use a next-generation form of CRISPR called base editing. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Cidara Therapeutics (NASDAQ:CDTX) shares rose 14.6% to $0.64 during Monday's pre-market session. The market value of their outstanding shares is at $44.9 million. The company's, Q3 earnings... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Good morning, investor! We're diving into the biggest pre-market stock movers for Monday as we get ready for another week of trading! 
Via InvestorPlace
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics Announces Publication of VERVE-101 Preclinical Data in Circulation and Presentations at the American Heart Association Annual Meeting
Verve Researchers Awarded Paul Dudley White International Scholar Award from the American Heart Association for Highest Ranked Abstract Submitted from the United States to Scientific Sessions 2022 
From Verve Therapeutics
Via GlobeNewswire
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
A Look Into Healthcare Sector Value Stocks
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base... 
Via Benzinga
Verve's Stock Price Could Continue To Rise Through Clinical Progress - Despite Worries About "DeeperPocketed" Competition
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2022
Upgrades 
Via Benzinga
Cathie Wood Just Bought the TSLA Stock Dip. Should You?
Cathie Wood is doubling down on TSLA stock. Here's why investors may want to follow her lead before markets shift in 2023. 
Via InvestorPlace
A Look Into Healthcare Sector Value Stocks
The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base... 
Via Benzinga
5 Top Stocks Cathie Wood Is Buying This Week
There's a new Ark fund in town, and its name is the ARK Venture Fund. It will capitalize on democratizing private investments to the public. 
Via InvestorPlace
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
Gainers 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.